StreetInsider.com News Articles

Inhibrx Biosciences (INBX) Reiterated at Market Perform by Citizens as Ozekibart Ph1 Started

Thu, 27 Aug 2026 04:32:44 -0400

Citizens analyst Reni Benjamin reiterated a Market Perform rating on Inhibrx Biosciences (NASDAQ: INBX).

The analyst commented, "We maintain our Market Perform rating on Inhibrx Biosciences based on a revenue and earnings multiple analysis, in addition to a cash/share and platform value analysis. Recently, Inhibrx reported 2Q26 financial results and provided corporate updates, including the initiation of two Phase 1 cohorts evaluating ozekibart in CRC. With $219.5MM (pro-forma) in cash, Inhibrx is well-capitalized to continue developing ozekibart and INBRX-106 to key milestones expected in 2026 and 2027. That said, with increasing competition in both the HNSCC and CRC landscape, and the

H.C. Wainwright Starts Inhibrx Biosciences (INBX) at Buy

Mon, 24 Aug 2026 06:07:39 -0400

H.C. Wainwright analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ: INBX) with a Buy rating and a price target of $245.00.

For an analyst ratings summary and ratings history on Inhibrx Biosciences click here. For more ratings news on Inhibrx Biosciences click here.

Shares of Inhibrx Biosciences closed at $103.63 yesterday.

H.C. Wainwright Starts Inhibrx Biosciences (INBX) at Buy

Mon, 24 Aug 2026 06:07:39 -0400

H.C. Wainwright analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ: INBX) with a Buy rating and a price target of $245.00.

For an analyst ratings summary and ratings history on Inhibrx Biosciences click here. For more ratings news on Inhibrx Biosciences click here.

Shares of Inhibrx Biosciences closed at $103.63 yesterday.

Inhibrx Biosciences (INBX) Reiterated at Buy by Stifel After Meet with CEO, CFO

Fri, 21 Aug 2026 07:46:15 -0400

Stifel analyst Dara Azar reiterated a Buy rating and $325.00 price target on Inhibrx Biosciences (NASDAQ: INBX).

The analyst commented, "We recently hosted a series of investor meetings with Mark Lappe (Founder, CEO) and Kelly Deck (EVP, CFO). We view the setup into the first disclosure of randomized durability data with INBRX-106 (OX40) next month as attractive and reasonably downside-protected, with INBX trading near last year's highs after chondrosarcoma P3 success and well before any growth-pipeline disclosures. While we maintain the view that the theoretical upside of the two pipeline-in-a-drug assets remains difficult to fully characterize, we note with each successive

Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26932840.html

Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26932840.html

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: Schonfeld Strategic Advisors LLC

Fri, 14 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26930935.html

Form SCHEDULE 13G Inhibrx Biosciences, Filed by: Schonfeld Strategic Advisors LLC

Fri, 14 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260814/26930935.html

Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP

Fri, 14 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26930702.html

Form SCHEDULE 13G/A Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP

Fri, 14 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260814/26930702.html

Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c

Thu, 13 Aug 2026 16:52:22 -0400

Inhibrx, Inc. (NASDAQ: INBX) reported Q2 EPS of ($2.34), $0.54 worse than the analyst estimate of ($1.80).

For earnings history and earnings-related data on Inhibrx, Inc. (INBX) click here.

Form 8-K Inhibrx Biosciences, For: Aug 13

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921082.html

Form 8-K Inhibrx Biosciences, For: Aug 13

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921082.html

Form 10-Q Inhibrx Biosciences, For: Jun 30

Thu, 13 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26920638.html

Form 10-Q Inhibrx Biosciences, For: Jun 30

Thu, 13 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26920638.html

Inhibrx Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 16:04:00 -0400

SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.